<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35215365</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">253</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph15020253</ELocationID><Abstract><AbstractText>Ultramicronized palmitoylethanolamide (um-PEA), a compound with antioxidant, anti-inflammatory and neuroprotective properties, appears to be a potential adjuvant treatment for early stages of Coronavirus disease 2019 (COVID-19). In our study, we enrolled 90 patients with confirmed diagnosis of COVID-19 that were randomized into two groups, homogeneous for age, gender and BMI. The first group received oral supplementation based on um-PEA at a dose of 1800 mg/day for a total of 28 days; the second group was the control group (R.S. 73.20). At baseline (T0) and after 28 days of um-PEA treatment (T1), we monitored: routine laboratory parameters, inflammatory and oxidative stress (OS) biomarkers, lymphocytes subpopulation and COVID-19 serological response. At T1, the um-PEA-treated group presented a significant reduction in inflammation compared to the control group (CRP <i>p</i> = 0.007; IL-6 <i>p</i> = 0.0001; neutrophils to lymphocytes ratio <i>p</i> = 0.044). At T1, the controls showed a significant increase in OS compared to the treated group (FORT <i>p</i> = 0.05). At T1, the um-PEA group exhibited a significant decrease in D-dimer levels (<i>p</i> = 0.0001) and higher levels of IgG against SARS-CoV-2 (<i>p</i> = 0.0001) compared to the controls. Our data demonstrated, in a randomized clinical trial, the beneficial effects of um-PEA in both asymptomatic and mild-symptomatic patients related to reductions in inflammatory state, OS and coagulative cascade alterations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5113-2017</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrone</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5854-2086</Identifier><AffiliationInfo><Affiliation>UOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paolino</LastName><ForeName>Agostino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Lauro</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8118-1330</Identifier><AffiliationInfo><Affiliation>UOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Daniele</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>PhD School of Applied Medical, Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UOSD of Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiaramonte</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostini</LastName><ForeName>Cartesio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Clinical Microbiology, Policlinico Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romani</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PHYTOLAB (Pharmaceutical, Cosmetic, Food Supplement, Technology and Analysis), DiSIA, University of Florence, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavaliere</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinic Department of Gynecology Fabia Mater, 00171 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerriero</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6104-6059</Identifier><AffiliationInfo><Affiliation>UOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magrini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercuri</LastName><ForeName>Nicola Biagio</ForeName><Initials>NB</Initials><Identifier Source="ORCID">0000-0001-6700-7491</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Santa Lucia Foundation, 00179 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Daniele</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7671-0015</Identifier><AffiliationInfo><Affiliation>UOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noce</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1310-3730</Identifier><AffiliationInfo><Affiliation>UOC of Internal Medicine-Center of Hypertension and Nephrology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adjuvant treatment</Keyword><Keyword MajorTopicYN="N">cytokines storm</Keyword><Keyword MajorTopicYN="N">long COVID syndrome</Keyword><Keyword MajorTopicYN="N">oral food supplement</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">um-PEA</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35215365</ArticleId><ArticleId IdType="pmc">PMC8878249</ArticleId><ArticleId IdType="doi">10.3390/ph15020253</ArticleId><ArticleId IdType="pii">ph15020253</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Renu K., Prasanna P.L., Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage&#x2014;A review. Life Sci. 2020;255:117839. doi: 10.1016/j.lfs.2020.117839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117839</ArticleId><ArticleId IdType="pmc">PMC7243768</ArticleId><ArticleId IdType="pubmed">32450165</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokkas T. Gastrointestinal involvement in COVID-19: A systematic review and meta-analysis. Ann. Gastroenterol. 2020;33:355&#x2013;365. doi: 10.20524/aog.2020.0506.</Citation><ArticleIdList><ArticleId IdType="doi">10.20524/aog.2020.0506</ArticleId><ArticleId IdType="pmc">PMC7315709</ArticleId><ArticleId IdType="pubmed">32624655</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong J., Bartell N., Peeraphatdit T., Mosli M., Al-Judaibi B. Gastrointestinal and liver manifestations of COVID-19. Saudi J. Gastroenterol. 2020;26:226&#x2013;232. doi: 10.4103/sjg.SJG_147_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/sjg.SJG_147_20</ArticleId><ArticleId IdType="pmc">PMC7739995</ArticleId><ArticleId IdType="pubmed">32367837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolhe N.V., Fluck R.J., Selby N.M., Taal M.W. Acute kidney injury associated with COVID-19: A retrospective cohort study. PLoS Med. 2020;17:e1003406. doi: 10.1371/journal.pmed.1003406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003406</ArticleId><ArticleId IdType="pmc">PMC7598516</ArticleId><ArticleId IdType="pubmed">33125416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad I., Rathore F.A. Neurological manifestations and complications of COVID-19: A literature review. J. Clin. Neurosci. 2020;77:8&#x2013;12. doi: 10.1016/j.jocn.2020.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2020.05.017</ArticleId><ArticleId IdType="pmc">PMC7200361</ArticleId><ArticleId IdType="pubmed">32409215</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneshgaran G., Dubin D.P., Gould D.J. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am. J. Clin. Dermatol. 2020;21:627&#x2013;639. doi: 10.1007/s40257-020-00558-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40257-020-00558-4</ArticleId><ArticleId IdType="pmc">PMC7456663</ArticleId><ArticleId IdType="pubmed">32865778</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020;92:552&#x2013;555. doi: 10.1002/jmv.25728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25728</ArticleId><ArticleId IdType="pmc">PMC7228394</ArticleId><ArticleId IdType="pubmed">32104915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritas S.K., Ronconi G., Caraffa A., Gallenga C.E., Ross R., Conti P. Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy. J. Biol. Regul. Homeost. Agents. 2020;34:9&#x2013;14. doi: 10.23812/20-Editorial-Kritas.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-Editorial-Kritas</ArticleId><ArticleId IdType="pubmed">32013309</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Zhong S., Liu J., Li L., Li Y., Wu X., Li Z., Deng P., Zhang J., Zhong N., et al. Detection of severe acute respiratory syndrome coronavirus in the brain: Potential role of the chemokine mig in pathogenesis. Clin. Infect. Dis. 2005;41:1089&#x2013;1096. doi: 10.1086/444461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/444461</ArticleId><ArticleId IdType="pmc">PMC7107994</ArticleId><ArticleId IdType="pubmed">16163626</ArticleId></ArticleIdList></Reference><Reference><Citation>Menghini R., Campia U., Tesauro M., Marino A., Rovella V., Rodia G., Schinzari F., Tolusso B., di Daniele N., Federici M., et al. Toll-like receptor 4 mediates endothelial cell activation through NF-kappaB but is not associated with endothelial dysfunction in patients with rheumatoid arthritis. PLoS ONE. 2014;9:e99053. doi: 10.1371/journal.pone.0099053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0099053</ArticleId><ArticleId IdType="pmc">PMC4053330</ArticleId><ArticleId IdType="pubmed">24918924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J., Hlh Across Speciality Collaboration U.K. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Steardo L., Jr., Bronzuoli M.R., Iacomino A., Esposito G., Steardo L., Scuderi C. Does neuroinflammation turn on the flame in Alzheimer&#x2019;s disease? Focus on astrocytes. Front. Neurosci. 2015;9:259. doi: 10.3389/fnins.2015.00259.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00259</ArticleId><ArticleId IdType="pmc">PMC4518161</ArticleId><ArticleId IdType="pubmed">26283900</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuderi C., Stecca C., Iacomino A., Steardo L. Role of astrocytes in major neurological disorders: The evidence and implications. IUBMB Life. 2013;65:957&#x2013;961. doi: 10.1002/iub.1223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.1223</ArticleId><ArticleId IdType="pubmed">24376207</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfopoulou S., Brown J.R., Davies E.G., Anderson G., Virasami A., Qasim W., Chong W.K., Hubank M., Plagnol V., Desforges M., et al. Human Coronavirus OC43 Associated with Fatal Encephalitis. N. Engl. J. Med. 2016;375:497&#x2013;498. doi: 10.1056/NEJMc1509458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1509458</ArticleId><ArticleId IdType="pubmed">27518687</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins V., Sohaei D., Diamandis E.P., Prassas I. COVID-19: From an acute to chronic disease? Potential long-term health consequences. Crit. Rev. Clin. Lab. Sci. 2021;58:297&#x2013;310. doi: 10.1080/10408363.2020.1860895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1860895</ArticleId><ArticleId IdType="pubmed">33347790</ArticleId></ArticleIdList></Reference><Reference><Citation>Goertz Y.M.J., Van Herck M., Delbressine J.M., Vaes A.W., Meys R., Machado F.V.C., Houben-Wilke S., Burtin C., Posthuma R., Franssen F.M.E., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res. 2020;6 doi: 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Center For Disease Control and Prevention &#x201c;SymptomDuration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network&#x2014;United States, March&#x2013;June 2020&#x201d;.  [(accessed on 3 December 2021)]; Available online:  https://www.cdc.gov/mmwr/volumes/69/wr/mm6930e1.htm#References.</Citation></Reference><Reference><Citation>Carfi A., Bernabei R., Landi F., Gemelli Against C.-P.-A.C.S.G. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou F., Hen R. 5-Hydroxytryptamine receptor subtypes: Molecular and functional diversity. Adv. Pharmacol. 1994;30:327&#x2013;380. doi: 10.1016/s1054-3589(08)60178-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1054-3589(08)60178-7</ArticleId><ArticleId IdType="pubmed">7833295</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Tan C., Wu J., Chen M., Wang Z., Luo L., Zhou X., Liu X., Huang X., Yuan S., et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir. Res. 2020;21:163. doi: 10.1186/s12931-020-01429-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01429-6</ArticleId><ArticleId IdType="pmc">PMC7323373</ArticleId><ArticleId IdType="pubmed">32600344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.M., Shang Y.M., Song W.B., Li Q.Q., Xie H., Xu Q.F., Jia J.L., Li L.M., Mao H.L., Zhou X.M., et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. eClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini E. A comprehensive review of COVID-19 characteristics. Biol. Proced. Online. 2020;22:19. doi: 10.1186/s12575-020-00128-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12575-020-00128-2</ArticleId><ArticleId IdType="pmc">PMC7402395</ArticleId><ArticleId IdType="pubmed">32774178</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Schiano Moriello A., Cerrato S., Fusco M., Puigdemont A., De Petrocellis L., Di Marzo V. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br. J. Pharmacol. 2016;173:1154&#x2013;1162. doi: 10.1111/bph.13084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13084</ArticleId><ArticleId IdType="pmc">PMC5338153</ArticleId><ArticleId IdType="pubmed">25598150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti A., Lazzari M., Gianfelice V., Di Paolo A., Sabato E., Sabato A.F. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13:1121&#x2013;1130. doi: 10.1111/j.1526-4637.2012.01432.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4637.2012.01432.x</ArticleId><ArticleId IdType="pubmed">22845893</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloe L., Leon A., Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39:C145&#x2013;C147. doi: 10.1007/BF01972748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01972748</ArticleId><ArticleId IdType="pubmed">7505999</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller V.L., Cichewicz D.L., Welch S.P. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur. J. Pharmacol. 2006;546:60&#x2013;68. doi: 10.1016/j.ejphar.2006.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2006.07.024</ArticleId><ArticleId IdType="pubmed">16919265</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., Mattace Raso G., Cuzzocrea S., Loverme J., Piomelli D., et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol. 2009;613:54&#x2013;59. doi: 10.1016/j.ejphar.2009.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2009.04.022</ArticleId><ArticleId IdType="pubmed">19386271</ArticleId></ArticleIdList></Reference><Reference><Citation>Luongo L., Guida F., Boccella S., Bellini G., Gatta L., Rossi F., de Novellis V., Maione S. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets. 2013;12:45&#x2013;54. doi: 10.2174/1871527311312010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527311312010009</ArticleId><ArticleId IdType="pubmed">23394524</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Fusco M., Della Valle M.F., Zusso M., Costa B., Giusti P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22:79&#x2013;94. doi: 10.1007/s10787-013-0191-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-013-0191-7</ArticleId><ArticleId IdType="pubmed">24178954</ArticleId></ArticleIdList></Reference><Reference><Citation>LoVerme J., Russo R., La Rana G., Fu J., Farthing J., Mattace-Raso G., Meli R., Hohmann A., Calignano A., Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 2006;319:1051&#x2013;1061. doi: 10.1124/jpet.106.111385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.106.111385</ArticleId><ArticleId IdType="pubmed">16997973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 1996;300:227&#x2013;236. doi: 10.1016/0014-2999(96)00015-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(96)00015-5</ArticleId><ArticleId IdType="pubmed">8739213</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Cesare Mannelli L., D&#x2019;Agostino G., Pacini A., Russo R., Zanardelli M., Ghelardini C., Calignano A. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: Pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediat. Inflamm. 2013;2013:328797. doi: 10.1155/2013/328797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/328797</ArticleId><ArticleId IdType="pmc">PMC3596927</ArticleId><ArticleId IdType="pubmed">23533304</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara S., Morimoto H., Ohori M., Yamada Y., Abe T., Arisaka O. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int. Arch. Allergy Immunol. 2005;138:80&#x2013;87. doi: 10.1159/000087361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000087361</ArticleId><ArticleId IdType="pubmed">16103691</ArticleId></ArticleIdList></Reference><Reference><Citation>Helyes Z., Nemeth J., Than M., Bolcskei K., Pinter E., Szolcsanyi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci. 2003;73:2345&#x2013;2353. doi: 10.1016/S0024-3205(03)00651-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0024-3205(03)00651-9</ArticleId><ArticleId IdType="pubmed">12941436</ArticleId></ArticleIdList></Reference><Reference><Citation>Naderi N., Majidi M., Mousavi Z., Khoramian Tusi S., Mansouri Z., Khodagholi F. The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-beta expression in rats. Neurochem. Res. 2012;37:778&#x2013;785. doi: 10.1007/s11064-011-0672-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-011-0672-2</ArticleId><ArticleId IdType="pubmed">22201038</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotini S., Schievano C., Guidi L. Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson&#x2019;s Disease. CNS Neurol. Disord. Drug Targets. 2017;16:705&#x2013;713. doi: 10.2174/1871527316666170321124949.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527316666170321124949</ArticleId><ArticleId IdType="pubmed">28325153</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelista M., Cilli, De Vitis R., Militerno A., Fanfani F. Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study. CNS Neurol. Disord. Drug Targets. 2018;17:291&#x2013;298. doi: 10.2174/1871527317666180420143830.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527317666180420143830</ArticleId><ArticleId IdType="pubmed">29676237</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Giorno R., Skaper S., Paladini A., Varrassi G., Coaccioli S. Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies. Pain Ther. 2015;4:169&#x2013;178. doi: 10.1007/s40122-015-0038-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-015-0038-6</ArticleId><ArticleId IdType="pmc">PMC4676767</ArticleId><ArticleId IdType="pubmed">26334329</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunardelli M.L., Crupi R., Siracusa R., Cocuzza G., Cordaro M., Martini E., Impellizzeri D., Di Paola R., Cuzzocrea S. Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations. CNS Neurol. Disord. Drug Targets. 2019;18:530&#x2013;554. doi: 10.2174/1871527318666190617162041.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527318666190617162041</ArticleId><ArticleId IdType="pubmed">31244434</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronzuoli M.R., Facchinetti R., Steardo L., Jr., Romano A., Stecca C., Passarella S., Steardo L., Cassano T., Scuderi C. Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer&#x2019;s Disease: In Vitro and In Vivo Evidence. Oxid. Med. Cell. Longev. 2018;2018:4720532. doi: 10.1155/2018/4720532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4720532</ArticleId><ArticleId IdType="pmc">PMC5822864</ArticleId><ArticleId IdType="pubmed">29576849</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S., Song Y., Peddie F., Evans A.M. Particle size reduction to the nanometer range: A promising approach to improve buccal absorption of poorly water-soluble drugs. Int. J. Nanomed. 2011;6:1245&#x2013;1251. doi: 10.2147/IJN.S19151.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S19151</ArticleId><ArticleId IdType="pmc">PMC3131191</ArticleId><ArticleId IdType="pubmed">21753876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen S., Mathew G., Joseph L. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int. J. Pharm. Investig. 2012;2:12&#x2013;17. doi: 10.4103/2230-973X.96921.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2230-973X.96921</ArticleId><ArticleId IdType="pmc">PMC3465159</ArticleId><ArticleId IdType="pubmed">23071955</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A., Albanese M., Marrone G., Di Lauro M., Pietroboni Zaitseva A., Palazzetti D., Guerriero C., Paolino A., Pizzenti G., Di Daniele F., et al. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals. 2021;14:336. doi: 10.3390/ph14040336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14040336</ArticleId><ArticleId IdType="pmc">PMC8067485</ArticleId><ArticleId IdType="pubmed">33917573</ArticleId></ArticleIdList></Reference><Reference><Citation>Putilina M.V., Grishin D.V. SARS-CoV-2 (COVID-19) as a Predictor of Neuroinflammation and Neurodegeneration: Potential Treatment Strategies. Neurosci. Behav. Physiol. 2021;51:577&#x2013;582. doi: 10.1007/s11055-021-01108-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11055-021-01108-z</ArticleId><ArticleId IdType="pmc">PMC8219508</ArticleId><ArticleId IdType="pubmed">34176996</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Daniele N., Di Renzo L., Noce A., Iacopino L., Ferraro P.M., Rizzo M., Sarlo F., Domino E., De Lorenzo A. Effects of Italian Mediterranean organic diet vs. low-protein diet in nephropathic patients according to MTHFR genotypes. J. Nephrol. 2014;27:529&#x2013;536. doi: 10.1007/s40620-014-0067-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-014-0067-y</ArticleId><ArticleId IdType="pubmed">24711158</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernyak B.V., Popova E.N., Prikhodko A.S., Grebenchikov O.A., Zinovkina L.A., Zinovkin R.A. COVID-19 and Oxidative Stress. Biochemistry. 2020;85:1543&#x2013;1553. doi: 10.1134/S0006297920120068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297920120068</ArticleId><ArticleId IdType="pmc">PMC7768996</ArticleId><ArticleId IdType="pubmed">33705292</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaprak E., Sukur Y.E., Ozmen B., Sonmezer M., Berker B., Atabekoglu C., Aytac R. Endometrial compaction is associated with the increased live birth rate in artificial frozen-thawed embryo transfer cycles. Hum. Fertil. 2021:1&#x2013;7. doi: 10.1080/14647273.2021.1966703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14647273.2021.1966703</ArticleId><ArticleId IdType="pubmed">34405774</ArticleId></ArticleIdList></Reference><Reference><Citation>Candi E., Tesauro M., Cardillo C., Lena A.M., Schinzari F., Rodia G., Sica G., Gentileschi P., Rovella V., Annicchiarico-Petruzzelli M., et al. Metabolic profiling of visceral adipose tissue from obese subjects with or without metabolic syndrome. Biochem. J. 2018;475:1019&#x2013;1035. doi: 10.1042/BCJ20170604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20170604</ArticleId><ArticleId IdType="pubmed">29437994</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Shen Y., Wang H., Ge Q., Fei A., Pan S. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study. Mediat. Inflamm. 2016;2016:8191254. doi: 10.1155/2016/8191254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/8191254</ArticleId><ArticleId IdType="pmc">PMC4823514</ArticleId><ArticleId IdType="pubmed">27110067</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthrie G.J., Charles K.A., Roxburgh C.S., Horgan P.G., McMillan D.C., Clarke S.J. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013;88:218&#x2013;230. doi: 10.1016/j.critrevonc.2013.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2013.03.010</ArticleId><ArticleId IdType="pubmed">23602134</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J., Kong J., Wang W., Wu M., Yao L., Wang Z., Jin J., Wu D., Yu X. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thromb. Res. 2020;192:3&#x2013;8. doi: 10.1016/j.thromres.2020.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7201241</ArticleId><ArticleId IdType="pubmed">32407937</ArticleId></ArticleIdList></Reference><Reference><Citation>So M.K.P., Tiwari A., Chu A.M.Y., Tsang J.T.Y., Chan J.N.L. Visualizing COVID-19 pandemic risk through network connectedness. Int. J. Infect. Dis. 2020;96:558&#x2013;561. doi: 10.1016/j.ijid.2020.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.011</ArticleId><ArticleId IdType="pmc">PMC7207126</ArticleId><ArticleId IdType="pubmed">32437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiurchiu V., Leuti A., Smoum R., Mechoulam R., Maccarrone M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. FASEB J. 2018;32:5716&#x2013;5723. doi: 10.1096/fj.201800107R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201800107R</ArticleId><ArticleId IdType="pubmed">29879374</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami M., Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev. Hematol. 2020;13:1265&#x2013;1275. doi: 10.1080/17474086.2020.1831383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2020.1831383</ArticleId><ArticleId IdType="pubmed">32997543</ArticleId></ArticleIdList></Reference><Reference><Citation>Magadum A., Engel F.B. PPARbeta/delta: Linking Metabolism to Regeneration. Int. J. Mol. Sci. 2018;19 doi: 10.3390/ijms19072013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19072013</ArticleId><ArticleId IdType="pmc">PMC6073704</ArticleId><ArticleId IdType="pubmed">29996502</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A., Vidiri M.F., Marrone G., Moriconi E., Bocedi A., Capria A., Rovella V., Ricci G., De Lorenzo A., Di Daniele N. Is low-protein diet a possible risk factor of malnutrition in chronic kidney disease patients? Cell Death Discov. 2016;2:16026. doi: 10.1038/cddiscovery.2016.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddiscovery.2016.26</ArticleId><ArticleId IdType="pmc">PMC4979484</ArticleId><ArticleId IdType="pubmed">27551517</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>